22-28725012-T-C
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 0P and 0B.
The NM_007194.4(CHEK2):c.557A>G(p.Asn186Ser) variant causes a missense change. The variant allele was found at a frequency of 0.0000155 in 1,613,958 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. N186H) has been classified as Likely benign.
Frequency
Consequence
NM_007194.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152130Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000318 AC: 8AN: 251416Hom.: 0 AF XY: 0.0000368 AC XY: 5AN XY: 135896
GnomAD4 exome AF: 0.0000164 AC: 24AN: 1461828Hom.: 0 Cov.: 32 AF XY: 0.0000206 AC XY: 15AN XY: 727216
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152130Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74324
ClinVar
Submissions by phenotype
Familial cancer of breast Uncertain:5
- -
This variant is classified as a variant of uncertain significance as there is insufficient evidence to determine its impact on protein function and/or cancer risk. -
This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 186 of the CHEK2 protein (p.Asn186Ser). This variant is present in population databases (rs369223840, gnomAD 0.01%). This missense change has been observed in individual(s) with breast cancer (PMID: 27783279). This variant is also known as c.686A>G (p.N229S). ClinVar contains an entry for this variant (Variation ID: 219529). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. RNA analysis performed to evaluate the impact of this missense change on mRNA splicing indicates it does not significantly alter splicing (internal data). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
- -
- -
not specified Uncertain:2
- -
- -
not provided Uncertain:2
Reported in individuals with a personal and/or family history of breast, ovarian, and other cancers, and also in unaffected control groups (PMID: 27783279, 30287823, 36243179, 33850299); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Also known as c.686A>G; p.(N229S); This variant is associated with the following publications: (PMID: 25420024, 30287823, 23911319, 26818556, 25417114, 28555940, 31398194, 27783279, 19782031, 22419737, 36243179, 34482403, 33850299) -
The CHEK2 c.557A>G (p.Asn186Ser) variant has been reported in the published literature in individuals with a personal and/or family history of breast cancer (PMID: 27783279 (2016), 33471991 (2021), see also http://databases.lovd.nl/shared/genes/CHEK2)). This variant has also been identified in reportedly healthy individuals (PMID: 28779002 (2017), 30287823 (2018), 33471991 (2021), 36243179 (2022), see also http://databases.lovd.nl/shared/genes/CHEK2)). The frequency of this variant in the general population, 0.00012 (4/34588 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, we are unable to determine the clinical significance of this variant. -
Hereditary cancer-predisposing syndrome Uncertain:2
The p.N186S variant (also known as c.557A>G), located in coding exon 3 of the CHEK2 gene, results from an A to G substitution at nucleotide position 557. The asparagine at codon 186 is replaced by serine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. This variant was reported as functional in a study assessing CHEK2-complementation through quantification of KAP1 phosphorylation and CHK2 autophosphorylation in human RPE1-CHEK2-knockout cells (Stolarova L et al. Clin Cancer Res 2023 Aug;29(16):3037-3050). In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
This missense variant replaces asparagine with serine at codon 186 of the CHEK2 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant (also known as p.Asn229Ser in the literature) has been reported in an individual with personal and/or family history of breast cancer (PMID: 27783279). This variant has also been identified in 8/251416 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Li-Fraumeni syndrome 2 Uncertain:1
- -
Malignant tumor of breast Uncertain:1
- -
Bone osteosarcoma;C2931456:Familial prostate cancer;C5882668:Li-Fraumeni syndrome 2 Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at